Evidence map›Paper›PMID 37445759›Full record

ArticleInternational journal of molecular sciences2023

Investigation of Anticancer Properties of Monoterpene-Aminopyrimidine Hybrids on A2780 Ovarian Cancer Cells.

Viktória Nagy, Raji Mounir, Gábor J Szebeni, Zsolt Szakonyi, Nikolett Gémes, Renáta Minorics, Péter Germán, István Zupkó

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Viktória NagyInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary.
Raji MounirInstitute of Pharmaceutical Chemistry, University of Szeged, H-6720 Szeged, Hungary.
Gábor J SzebeniLaboratory of Functional Genomics, Eötvös Loránd Research Network Biological Research Centre, Institute of Genetics, H-6726 Szeged, Hungary.ORCID 0000-0002-6998-5632
Zsolt SzakonyiInstitute of Pharmaceutical Chemistry, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0003-2432-8409
Nikolett GémesLaboratory of Functional Genomics, Eötvös Loránd Research Network Biological Research Centre, Institute of Genetics, H-6726 Szeged, Hungary.
Renáta MinoricsInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary.
Péter GermánInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary.
István ZupkóInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0003-3243-5300
University of Szeged · HUHUN-REN Szegedi Biológiai Kutatóközpont · HU

Funding

Hungarian Academy of Sciences BO/00582/22/8Hungarian Research Foundation 2020-1.1.6-JÖVŐ-2021-00003Hungarian Research Foundation K 143690, 142877 FK22Ministry of Innovation and Technology of Hungary TKP2021-EGA-32
6 · The paper itself

Abstract

The present study aimed to characterize the antiproliferative and antimetastatic properties of two recently synthesized monoterpene-aminopyrimidine hybrids (

Indexed as

Antineoplastic AgentsOvarian NeoplasmsApoptosisCell Line, TumorCell ProliferationFemaleHumansPyrimidines2-aminopyrimidineAntineoplastic AgentsPyrimidinesaminoalcoholantimetastaticantiproliferativeG2/M arrestmonoterpeneovarian cancer

Identifiers

PMID37445759
PMCPMC10341452
OpenAlexW4382068346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.